Eric J. Feldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric J. Feldman has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Phillip M. Garfin
Seattle Genetics, Inc., 21823-30th Drive Southeast, Bothell, WA, 98021, USA
1 shared publication
Latest Publications
- 12 October 2016
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 11 (6) , 545-552
Antibody-Based Treatment of Acute Myeloid Leukemia
While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.
- 12 October 2016
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 11 (6) , 545-552
Antibody-Based Treatment of Acute Myeloid Leukemia
While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S91-S93
Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S91-S93
Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014